Taysha Gene Therapies, Inc. Research and Development in Process
Taysha Gene Therapies, Inc. (TSHA) reported Research and Development in Process of $3.50 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-08-14
- Taysha Gene Therapies, Inc. research and development in process for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Taysha Gene Therapies, Inc. research and development in process for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Taysha Gene Therapies, Inc. research and development in process for the quarter ending 2022-06-30 was $0.00.
- Taysha Gene Therapies, Inc. research and development in process for the quarter ending 2022-03-31 was $1.25M, a 77.27% decline year-over-year.
- Taysha Gene Therapies, Inc. research and development in process for fiscal 2022 was $1.25M, a 87.18% decline from fiscal 2021.
- Taysha Gene Therapies, Inc. research and development in process for fiscal 2021 was $9.75M, a 8.33% increase from fiscal 2020.
- Taysha Gene Therapies, Inc. research and development in process for fiscal 2020 was $9.00M.
| Period end | Research and Development in Process 0 month | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|---|
| 2023-06-30 | $3.50M 10-Q · filed 2023-08-14 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $0.00 derived: sum of 2 quarters · filed 2023-03-28 | $0.00 derived: sum of 3 quarters · filed 2023-08-14 | $1.25M 10-K · filed 2023-03-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-08-14 | $1.25M 10-Q · filed 2022-11-08 | $4.25M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.25M 10-Q · filed 2023-08-14 | $4.25M derived: sum of 3 quarters · filed 2023-08-14 | $5.50M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $1.25M 10-Q · filed 2023-05-11 | $4.25M derived: sum of 2 quarters · filed 2023-05-11 | $5.50M derived: sum of 3 quarters · filed 2023-05-11 | $5.50M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $4.25M derived: sum of 2 quarters · filed 2023-03-28 | $4.25M derived: sum of 3 quarters · filed 2023-03-28 | $9.75M 10-K · filed 2023-03-28 | |
| 2021-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.25M derived: sum of 2 quarters · filed 2022-11-08 | $6.75M 10-Q · filed 2022-11-08 | $9.75M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $5.50M 10-Q · filed 2022-08-11 | $8.50M derived: sum of 3 quarters · filed 2022-08-11 | $11.50M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $5.50M 10-Q · filed 2022-05-16 | $8.50M derived: sum of 2 quarters · filed 2022-05-16 | $11.50M derived: sum of 3 quarters · filed 2022-05-16 | $11.50M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $6.00M derived: sum of 2 quarters · filed 2022-03-31 | $6.00M derived: sum of 3 quarters · filed 2022-03-31 | $9.00M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $3.00M derived: sum of 2 quarters · filed 2021-11-10 | $6.00M 10-Q · filed 2021-11-10 | $6.98M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $3.00M 10-Q · filed 2021-08-16 | $3.98M derived: sum of 3 quarters · filed 2021-08-16 | ||
| 2020-03-31 | $3.00M 10-Q · filed 2021-05-11 | $3.98M derived: sum of 2 quarters · filed 2021-05-11 | |||
| 2019-12-31 | $980.00K 10-K · filed 2021-03-03 | ||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |